As compared with DLBCL_others, DLBCL with MYD88 L265P mutation still showed poor OS and PFS (p = 0.005 and 0.001, respectively), and the same to DLBCL with JAK2/PD-L2 amplification for PFS and OS (p = 0.006 and 0.001, respectively). Here, JAK2 is linked to diffuse large B-cell lymphoma.